Webinar Preview
Over the past decade, oncology care has undergone a remarkable transformation, driven by the advent of precision medicine. This revolution has been fueled by a deeper understanding of cancer’s biological underpinnings, leading to the development of biomarker-driven therapies. These therapies, tailored to individual patients’ genetic and molecular profiles, promise improved treatment outcomes and reduced side effects.
In this webinar, the expert speaker will explore the evolving role of diagnostic labs in the landscape of biomarker-driven oncology therapies. Traditionally, diagnostic labs have been key players in the healthcare continuum, primarily providing essential diagnostic services. However, with the rise of precision medicine, these labs are now at the forefront, acting as strategic partners in drug development and clinical implementation.
Read more...
The speaker will explore:
- The Rise of Biomarker-Driven Therapies: The attendees will get to understand how biomarkers are revolutionizing cancer treatment by offering targeted therapies that align with specific cancer subtypes. They will also learn about the pivotal role of biomarkers like human epidermal growth factor receptor 2 (HER2) in breast cancer and their impact on therapy development
- Shifting Dynamics in Drug Development: The attendees will get to discover how biomarker-driven approaches are streamlining drug development, reducing time to approval and increasing the success rates of new therapies. They will also get to explore the collaborative efforts between pharmaceutical companies and diagnostic labs that are expediting this process
- The Changing Role of Diagnostic Labs: The attendees will also get to examine how diagnostic labs have transitioned from service providers to proactive partners in oncology care. They will also get to learn about their early involvement in clinical trials and the development of companion diagnostics, ensuring accurate and timely treatment allocation
This webinar will highlight the collaborative synergy among pharmaceutical companies, diagnostic labs and healthcare providers, emphasizing the integrated approach necessary for advancing patient care. The speaker will discuss real-world examples and case studies, providing attendees with a comprehensive understanding of how precision medicine is reshaping the future of oncology. He will offer valuable insights into the dynamic role of diagnostic labs in the era of precision medicine and explore the promises and challenges that lie ahead on collectively driving better outcomes for cancer patients.
Read Less...
Register for this webinar today that will delve into the transformative impact of precision medicine on oncology care and highlight the evolving role of diagnostic labs in the era of biomarker-driven therapies.
Speaker
Dr. Yuri Fesko, MD, Chief Medical Officer, Quest Diagnostics
Located in the New York City Metropolitan Area, Dr. Yuri Fesko is a board-certified Medical Oncologist and the Chief Medical Officer at Quest Diagnostics. With over two decades of experience in clinical practice and medical leadership, Dr. Fesko leads the company’s medical affairs, clinical development, and strategic medical initiatives – particularly in oncology diagnostics and precision medicine.
He has pioneered innovative diagnostic solutions, including the development of the next-generation sequencing panel and decentralized clinical trials, enhancing patient care and healthcare affordability. An active speaker and published author, Dr. Fesko’s work continues to influence global healthcare advancements.
Message PresenterWho Should Attend?
This webinar is ideal for professionals in the pharmaceutical industry, particularly those involved in oncology drug development and precision medicine. Key attendees include:
- Pharma industry professionals focused on oncology and precision medicine drug development
- Clinical researchers and scientists engaged in biomarker research
- Decision-makers and strategists seeking to enhance their understanding of biomarker-driven therapies and their impact on drug development
What You Will Learn
Attendees will learn about:
- The pivotal role of biomarkers in developing targeted cancer therapies
- How biomarker-driven approaches are streamlining the drug development process
- The evolving responsibilities of diagnostic labs in precision oncology
- Real-world examples of collaborative efforts between pharmaceutical companies and diagnostic labs
Xtalks Partner
Quest Diagnostics
When you choose Quest Diagnostics as your partner in BioPharma Services, you get more than lab testing. Access the reach, expertise, and renowned quality of Quest Diagnostics for every milestone of your program—from R&D consulting through clinical trials, companion diagnostic development, commercialization, and post-launch surveillance. Together we have the power to deliver better outcomes.
Related Webinars
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account